US 2003/0215466 A1Published application

Modified vaccinia ankara virus variant

AssigneeBavarian Nordic A/S

InventorsPaul Chaplin, Paul Howley, Christine Meisinger

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.

Claims29

Dependent claims

1) a method for inducing a specific immune response in a living animal body, including a human, comprising administering an amount of a vaccinia preparation which includes an effective amount of a vaccinia virus having at least one of the following advantageous properties:

(i) capability of reproductive replication in vitro in chicken embryo fibroblasts (CEF), but no capability of reproductive replication in a human cell line known to permit replication with known vaccinia strains,
(ii) failure to replicate in vivo in those animals including humans in which the virus is used as a vaccine or active ingredient of a pharmaceutical composition,
(iii) induction of a higher specific immune response compared to a known vaccinia strain, and/or
(iv) induction of at least the same level of a specific immune response in vaccinia virus prime/vaccinia virus boost regimes when compared to DNA-prime/vaccinia virus boost regimes,
wherein the living animal to which the preparation is administered is immune compromised.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application: 10/440,073Filed 16 May 2003
Priority: DK PA 2000 0176423 Nov 2000
Published: 20 Nov 2003
Term ends: Not estimatedThe source records don’t support an estimate.

Classification28 codes

C07K 14/005
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from viruses
A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
A61K 39/285
Poxviridae, e.g. avipoxvirus: vaccinia virus or variola virus
A61P 31/00
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Family

Application10/440,073Continuation · filed 16 May 2003
US 7,189,536 B2Related patent
US 2003/0215466 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key